Sanofi SA ((SNY)), Sanofi ((SNYNF)), Sanofi ((DE:SNW)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sanofi SA has initiated a Phase 2 clinical study titled ‘A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)’. The study aims to evaluate the efficacy of this combination in patients who have undergone 1 to 3 prior treatments, focusing on the overall response rate.
The intervention involves the experimental use of Isatuximab administered subcutaneously via an on-body delivery system, combined with weekly doses of Carfilzomib and Dexamethasone. This treatment targets improving outcomes for patients with relapsed or refractory multiple myeloma.
This is a single-group, open-label study with no masking, primarily aimed at treatment. Participants will undergo a 12-month treatment period, with a 28-day cycle structure, followed by a follow-up until death or study cut-off.
The study officially started on March 17, 2025, with the primary completion and estimated completion dates yet to be announced. The latest update was submitted on June 30, 2025, indicating ongoing recruitment.
This study could potentially impact Sanofi’s stock performance positively if successful, as it addresses a significant need in multiple myeloma treatment. Competitors in the oncology space may closely watch these developments, as advancements could shift market dynamics.
The study is currently recruiting, with further details available on the ClinicalTrials portal.